Your browser is no longer supported. Please, upgrade your browser.
Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-1.37 Insider Own0.30% Shs Outstand97.60M Perf Week-2.42%
Market Cap919.31M Forward P/E- EPS next Y-2.00 Insider Trans9.14% Shs Float96.74M Perf Month-17.66%
Income-117.50M PEG- EPS next Q-0.37 Inst Own97.60% Short Float11.75% Perf Quarter-25.89%
Sales- P/S- EPS this Y-37.20% Inst Trans-0.34% Short Ratio13.93 Perf Half Y-25.30%
Book/sh4.45 P/B1.99 EPS next Y-19.00% ROA-28.10% Target Price- Perf Year-23.75%
Cash/sh4.14 P/C2.14 EPS next 5Y- ROE-31.60% 52W Range8.75 - 26.98 Perf YTD-18.27%
Dividend- P/FCF- EPS past 5Y5.80% ROI- 52W High-67.16% Beta1.41
Dividend %- Quick Ratio20.80 Sales past 5Y- Gross Margin- 52W Low1.26% ATR0.63
Employees167 Current Ratio20.80 Sales Q/Q- Oper. Margin- RSI (14)37.31 Volatility5.57% 6.79%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.70% Profit Margin- Rel Volume1.32 Prev Close9.40
ShortableYes LT Debt/Eq0.00 EarningsMar 01 AMC Payout- Avg Volume815.56K Price8.86
Recom2.10 SMA20-9.43% SMA50-22.09% SMA200-31.82% Volume1,075,277 Change-5.74%
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20Downgrade Raymond James Mkt Perform → Underperform
May-13-20Initiated RBC Capital Mkts Outperform $24
May-05-20Upgrade SunTrust Hold → Buy $13 → $21
Apr-28-20Initiated Goldman Buy $17
Mar-16-20Initiated SVB Leerink Outperform $17
Feb-10-20Upgrade Chardan Capital Markets Neutral → Buy $20
Feb-10-20Upgrade Cantor Fitzgerald Neutral → Overweight $8 → $21
Oct-15-19Reiterated Chardan Capital Markets Neutral $6 → $10
Sep-13-19Reiterated Chardan Capital Markets Neutral $10 → $6
Jun-14-19Resumed Raymond James Mkt Perform
Nov-02-18Downgrade SunTrust Buy → Hold
Nov-02-18Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-30-18Initiated SunTrust Buy $11
Feb-15-18Resumed Piper Jaffray Overweight $12
Oct-12-17Initiated Raymond James Outperform $6
Apr-16-21 08:05AM  
Apr-15-21 08:00AM  
Apr-08-21 09:39AM  
Mar-30-21 09:00AM  
Mar-18-21 04:00PM  
Mar-17-21 05:10PM  
Mar-05-21 08:30AM  
Mar-02-21 07:31AM  
Mar-01-21 05:25PM  
Feb-22-21 04:00PM  
Feb-18-21 04:00PM  
Feb-10-21 04:49PM  
Feb-02-21 09:00AM  
Jan-21-21 11:02PM  
Jan-11-21 12:00PM  
Jan-08-21 08:49AM  
Jan-07-21 11:57AM  
Jan-05-21 09:00AM  
Dec-21-20 10:23AM  
Dec-14-20 09:00AM  
Nov-23-20 11:00AM  
Nov-14-20 10:00AM  
Nov-08-20 07:32AM  
Nov-05-20 06:35PM  
Oct-20-20 09:00AM  
Oct-09-20 08:56AM  
Sep-29-20 05:23PM  
Sep-15-20 08:00AM  
Sep-10-20 08:00AM  
Sep-08-20 08:57AM  
Aug-20-20 07:57AM  
Aug-18-20 09:00AM  
Aug-17-20 08:51AM  
Aug-12-20 09:37PM  
Aug-11-20 04:01PM  
Aug-10-20 05:35PM  
Jul-29-20 04:05PM  
Jul-21-20 08:00AM  
Jul-20-20 11:07AM  
Jul-13-20 08:30AM  
Jul-06-20 09:00AM  
Jun-30-20 11:50PM  
Jun-25-20 04:01PM  
Jun-16-20 08:13AM  
Jun-15-20 04:01PM  
Jun-04-20 04:05PM  
May-29-20 11:30AM  
May-28-20 05:45PM  
May-25-20 11:30AM  
May-21-20 04:05PM  
May-09-20 08:00AM  
May-07-20 11:30AM  
May-06-20 12:53PM  
May-05-20 04:11PM  
May-04-20 05:10PM  
May-03-20 07:00AM  
Apr-30-20 04:05PM  
Apr-28-20 12:00PM  
Apr-27-20 04:01PM  
Apr-20-20 04:05PM  
Apr-01-20 01:42AM  
Mar-26-20 08:55AM  
Mar-18-20 12:00PM  
Mar-16-20 06:06AM  
Mar-12-20 05:55PM  
Mar-11-20 04:38PM  
Mar-05-20 04:01PM  
Mar-04-20 04:25PM  
Mar-03-20 02:20PM  
Mar-02-20 05:50PM  
Feb-26-20 06:50PM  
Feb-25-20 03:00PM  
Feb-24-20 05:31PM  
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fischer LaurentCEO and DirectorMar 24Buy9.8810,00098,78026,292Mar 24 07:47 PM
Machado PatrickDirectorMar 24Buy9.9210,00099,19688,182Mar 24 07:46 PM
PATTERSON LEONE DPresident and CFOFeb 09Sale14.1012,533176,71897,955Feb 11 07:47 PM
Machado PatrickDirectorJan 15Buy11.5210,000115,17478,182Jan 19 08:33 PM
Fischer LaurentCEO and DirectorJan 15Buy11.538,60099,19116,292Jan 19 08:32 PM
Soparkar PeterChief Legal OfficerAug 17Buy13.007,69299,99610,692Aug 19 06:48 PM
Fischer LaurentCEO and DirectorAug 17Buy13.007,69299,9967,692Aug 19 06:45 PM
Gasmi MehdiDirectorJul 20Option Exercise4.805,00024,000279,442Jul 22 09:44 PM
Gasmi MehdiDirectorJul 20Sale17.605,00087,978274,442Jul 22 09:44 PM
Gasmi MehdiDirectorJun 22Option Exercise4.8023,605113,304298,047Jun 23 06:58 PM
Gasmi MehdiDirectorJun 22Sale25.0623,605591,617274,442Jun 23 06:58 PM
Gasmi MehdiDirectorJun 18Option Exercise4.8011,12753,410285,569Jun 18 09:45 PM
Gasmi MehdiDirectorJun 18Sale25.0111,127278,329274,442Jun 18 09:45 PM
Gasmi MehdiDirectorJun 17Option Exercise4.802681,286274,710Jun 18 09:45 PM
Gasmi MehdiDirectorJun 17Sale25.012686,703274,442Jun 18 09:45 PM
PATTERSON LEONE DPresidentJun 16Sale24.6813,171325,060110,488Jun 17 05:47 PM
Gasmi MehdiDirectorJun 15Option Exercise4.8010,00048,000284,442Jun 17 05:14 PM
Gasmi MehdiDirectorJun 15Sale21.8610,000218,627274,442Jun 17 05:14 PM
Gasmi MehdiDirectorMay 21Option Exercise4.803,59917,275278,041May 22 06:55 PM
Gasmi MehdiDirectorMay 20Option Exercise4.801,4016,725275,843May 22 06:55 PM
Gasmi MehdiDirectorMay 20Sale20.011,40128,030274,442May 22 06:55 PM
Gasmi MehdiDirectorMay 18Option Exercise4.805,00024,000279,442May 20 07:34 PM
Gasmi MehdiDirectorMay 18Sale18.175,00090,833274,442May 20 07:34 PM
Gasmi MehdiDirectorMay 06Option Exercise4.8025,000120,000299,442May 20 07:34 PM
PATTERSON LEONE DCEO, President and DirectorMay 06Option Exercise3.4420,00068,800143,659May 08 06:25 PM
Gasmi MehdiDirectorMay 06Sale20.0325,000500,668274,442May 20 07:34 PM
PATTERSON LEONE DCEO, President and DirectorMay 06Sale20.0220,000400,400123,659May 08 06:25 PM
Gasmi MehdiDirectorMay 05Option Exercise4.8010,00048,000284,442May 20 07:34 PM
Gasmi MehdiDirectorMay 05Sale16.2610,000162,573274,442May 20 07:34 PM
Scopa James PaulDirectorMay 04Option Exercise6.4823,334151,20453,334May 05 06:44 PM